ACAD ▼ -19.5% - ACADIA Pharmaceuticals Inc. $ACAD Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) 24-SEP-2026 07:00 AM ET